Search Results - "DeArbeloa, Patricia"

Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature by Gupta, Medhavi, Sherrow, Christopher, Krone, Maghan E, Blais, Edik M, Pishvaian, Michael J, Petricoin, Emanuel F, Matrisian, Lynn M, DeArbeloa, Patricia, Gregory, Gary, Brown, Alyson, Zalewski, Olivia, Prinzing, Gillian, Roche, Charles, Kanehira, Kazunori, Mukherjee, Sarbajit, Iyer, Renuka, Fountzilas, Christos

“…Pancreatic acinar cell carcinoma (PACC) is a rare pancreatic exocrine malignancy. Compared with the more common pancreatic ductal adenocarcinoma (PDAC), PACC…”
Get more information

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial by Pishvaian, Michael J, Blais, Edik M, Brody, Jonathan R, Lyons, Emily, DeArbeloa, Patricia, Hendifar, Andrew, Mikhail, Sam, Chung, Vincent, Sahai, Vaibhav, Sohal, Davendra P S, Bellakbira, Sara, Thach, Dzung, Rahib, Lola, Madhavan, Subha, Matrisian, Lynn M, Petricoin, Emanuel F

“…About 25% of pancreatic cancers harbour actionable molecular alterations, defined as molecular alterations for which there is clinical or strong preclinical…”
Get full text

Real-world timelines of BRCA1/2-related molecular testing in pancreatic cancer by Li, Weiyan, Amin, Suvina, Joo, Seongjung, Adeboyeje, Gboyega, DeArbeloa, Patricia, Petricoin, Emanuel, Blais, Edik Matthew, Pishvaian, Michael J.

“…Abstract only 601 Background: BRCA1/2 mutations are present in ̃6-8% of patients with pancreatic adenocarcinoma. Olaparib is a recently approved PARP inhibitor…”
Get full text

Real-world use of PARP inhibitors in BRCA1/2-mutated pancreatic cancer: A retrospective analysis by Amin, Suvina, Li, Weiyan, Joo, Seongjung, Adeboyeje, Gboyega, DeArbeloa, Patricia, Petricoin, Emanuel, Blais, Edik Matthew, Pishvaian, Michael J.

“…Abstract only 599 Background: BRCA1 or BRCA2 mutations can be found in approximately 6 to 8 percent of patients patients with metastatic pancreatic…”
Get full text

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC) by Pishvaian, Michael J., Blais, Edik Matthew, Thach, Dzung, Brody, Jonathan Robert, Matrisian, Lynn McCormick, Halverson, David Charles, DeArbeloa, Patricia, Rocha, Flavio G, Hendifar, Andrew Eugene, Petricoin, Emanuel

“…4149 Background: Nearly 50% of pts with mPDAC never receive a 2nd line of therapy for metastatic disease following frontline FFX or GA. Genomic alterations in…”
Get full text

Precision Oncology for Pancreatic Cancer across the United States: the Know Your Tumor ® experience by Matrisian, Lynn M., Blais, Edik M., Lyons, Emily, Moravek, Cassadie, Dearbeloa, Patricia, Madhavan, Subha, Brody, Jonathan R., Petricoin, Emanuel, Pishvaian, Michael J.

Get full text

SY4-2Precision Oncology for Pancreatic Cancer across the United States: the Know Your Tumor ® experience by Matrisian, Lynn M, Blais, Edik M, Lyons, Emily, Moravek, Cassadie, Dearbeloa, Patricia, Madhavan, Subha, Brody, Jonathan R, Petricoin, Emanuel, Pishvaian, Michael J

“…Abstract The Know Your Tumor initiative identifies pancreatic cancer patients across the USA eligible for molecular testing through the Pancreatic Cancer…”
Get full text

Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC) by Osipov, Arsen, Blais, Edik Matthew, Davelaar, John, Moshayedi, Natalie, Nikravesh, Nima, Gresham, Gillian, Zheng, Lei, McRee, Autumn Jackson, Chuy, Jennifer W., Shroff, Rachna T., Wadlow, Raymond Couric, Gregory, Gary Lee, DeArbeloa, Patricia, Matrisian, Lynn McCormick, Petricoin, Emanuel, Pishvaian, Michael J., Thomassian, Shant, Gong, Jun, Hendifar, Andrew Eugene

“…Abstract only 532 Background: PDAC remains one of the most lethal malignancies following metastatic presentation, typically to the liver or lung. Previous…”
Get full text

Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): Clinical/molecular correlations and real-world outcomes across standard therapies by Hendifar, Andrew Eugene, Blais, Edik Matthew, Ng, Camille, Thach, Dzung, Gong, Jun, Sohal, Davendra, Chung, Vincent, Sahai, Vaibhav, Fountzilas, Christos, Mikhail, Sameh, Gregory, Gary, Brody, Jonathan Robert, Lyons, Emily, DeArbeloa, Patricia, Matrisian, Lynn McCormick, Petricoin, Emanuel, Pishvaian, Michael J.

“…Abstract only 4641 Background: Approximately 90% of PDAC tumors are driven by activating KRAS mutations. The biological and clinical impact of common KRAS…”
Get full text

Real-world outcomes in pancreatic adenocarcinoma (PDAC) and persona types with implications for standard of care (SOC) therapy (Tx) by Petricoin, Emanuel, Pishvaian, Michael J., DeArbeloa, Patricia, Barg, Daniel, Thach, Dzung, Brody, Jonathan Robert, Matrisian, Lynn McCormick, Chung, Vincent, Hendifar, Andrew Eugene, Mikhail, Sameh, Sohal, Davendra, Blais, Edik Matthew

“…Abstract only 735 Background: Molecular profiling (MP) for PDAC has gained increased acceptance and we previously demonstrated that targeting actionable…”
Get full text

Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx) by Pishvaian, Michael J., Blais, Edik Matthew, DeArbeloa, Patricia, Brody, Jonathan Robert, Rahib, Lola, Hendifar, Andrew Eugene, Mikhail, Sameh, Chung, Vincent, Sohal, Davendra, Picozzi, Vincent J., Mason, Kimberly, Tibbetts, Lisa, Lyons, Emily, Matrisian, Lynn McCormick, Madhavan, Subha, Petricoin, Emanuel

“…Abstract only 4138 Background: Initial results from the KYT program demonstrated that 27% of PDACs harbor highly actionable molecular alterations (herein…”
Get full text

A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients by Pishvaian, Michael J, Blais, Edik M, Bender, R Joseph, Rao, Shruti, Boca, Simina M, Chung, Vincent, Hendifar, Andrew E, Mikhail, Sam, Sohal, Davendra P S, Pohlmann, Paula R, Moore, Kathleen N, He, Kai, Monk, Bradley J, Coleman, Robert L, Herzog, Thomas J, Halverson, David D, DeArbeloa, Patricia, Petricoin, 3rd, Emanuel F, Madhavan, Subha

“…Scalable informatics solutions that provide molecularly tailored treatment recommendations to clinicians are needed to streamline precision oncology in care…”
Get full text

Association of Pancreatic Adenocarcinoma Location With DNA Damage Response Status and Response to Platinum-Based Therapy by Micaily, Ida, Blais, Edik M, Carhart, Randi, Lam, Sophia, Cohen, Steven J, Cannaday, Shawna J, Halverson, David, Matrisian, Lynn M, DeArbeloa, Patricia, Thach, Dzung, Petricoin, 3rd, Emanuel, Pishvaian, Michael J, Lavu, Harish, Yeo, Charles J, Mallick, Atrayee Basu

“…Pancreatic adenocarcinoma is an aggressive disease with poor clinical outcomes. Primary pancreatic tumors originating from the head of the pancreas (H) have…”
Get more information